Neurocrine Biosciences NBIX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.1B+28.6% | $2.86B+21.4% | $2.68B+19.6% | $2.51B+18.4% | $2.41B+21.7% | ||
| $56.7M+58.8% | $52.1M+53.2% | $43.8M+31.9% | $37.8M+3.8% | $35.7M-7.8% | ||
| $3.05B+28.1% | $2.81B+21.0% | $2.64B+19.4% | $2.47B+18.7% | $2.38B+22.3% | ||
| 98.2%-0.3pp | 98.2%-0.4pp | 98.4%-0.2pp | 98.5%+0.2pp | 98.5%+0.5pp | ||
| $1.05B+25.6% | $1.02B+38.9% | $943.1M+38.1% | $888.1M+40.9% | $834.9M+42.7% | ||
| $1.2B+15.1% | $1.16B+14.8% | $1.14B+21.7% | $1.08B+19.5% | $1.04B+17.2% | ||
| $2.31B+20.6% | $2.24B+25.6% | $2.13B+28.2% | $2.01B+27.3% | $1.92B+26.4% | ||
| $788.9M+59.4% | $619.1M+8.5% | $550.2M-4.9% | $495M-7.7% | $494.8M+6.5% | ||
| 25.4%+4.9pp | 21.6%-2.6pp | 20.5%-5.3pp | 19.7%-5.6pp | 20.5%-2.9pp | ||
| $148.6M— | $86.3M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $937.5M+101% | $705.4M+45.1% | $628.6M+20.5% | $527.1M+17.9% | $466.2M-0.8% | ||
| $268.9M+67.6% | $226.8M+56.7% | $200.6M+47.8% | $178.8M+66.0% | $160.4M+60.1% | ||
| $668.6M+119% | $478.6M+40.2% | $428M+10.9% | $348.3M+2.7% | $305.8M-17.3% | ||
| 21.6%+8.9pp | 16.7%+2.2pp | 16%-1.3pp | 13.9%-2.1pp | 12.7%-6.0pp | ||
| $6.49+120% | $4.66+41.6% | $4.18+11.5% | $3.38+1.5% | $2.95-19.2% | ||
| $6.71+121% | $4.82+42.6% | $4.31+11.7% | $3.48+1.5% | $3.03-19.6% | ||
| 409.4M-1.2% | 408.5M-1.7% | 409.7M-0.8% | 411.5M+0.5% | 414.4M+2.1% | ||
| 398.4M-0.9% | 397.6M-1.1% | 398.5M-0.2% | 400.2M+1.0% | 402M+2.3% | ||
| —— | —— | -$8.6M-38.7% | -$56.1M-90.8% | -$69.3M-349% | ||
| $96.7M+7.0% | $90.3M-0.8% | $87M-0.5% | $88.2M+12.4% | $90.4M+36.1% | ||
| $660M+112% | $485.9M+42.9% | $426.7M+6.1% | $358.3M+4.5% | $311.5M-17.1% | ||
| $26.6M+7.3% | $26M+10.6% | $25.8M+16.2% | $24.7M+16.5% | $24.8M+30.5% | ||
| —— | —— | —— | —— | —— | ||
| $81.1M-62.8% | $81.4M-62.6% | $146.6M-23.2% | $197.2M+40.0% | $217.9M+323% | ||
| $148.9M+152% | $160.2M+269% | $161M— | $149.4M— | $59M— | ||
| —— | —— | $248.9M+294% | $129.5M+60.5% | $67.4M+6.8% | ||
| $9.3M-57.5% | $15.3M-19.9% | $23.5M— | $14.5M— | $21.9M— | ||
| -$10.9M-327% | $3.5M+3,600% | -$1.6M-113% | $8.4M+127% | $4.8M-9.4% | ||
| $34.8M-7.7% | $36.4M-4.7% | $43.7M+20.4% | $38.6M+7.8% | $37.7M+21.6% | ||
| $120.9M+43.4% | $129.4M+6.0% | $102.1M-30.8% | $82.9M-40.7% | $84.3M-33.6% | ||
| $38.5M+483% | $17.4M+39.2% | $3.4M-64.2% | $4.1M-51.8% | $6.6M+10.0% | ||
| $1.05B+25.6% | $1.02B+38.9% | $943.1M+38.1% | $888.1M+40.9% | $834.9M+42.7% | ||
| $3.1B+28.6% | $2.86B+21.4% | $2.68B+19.6% | $2.51B+18.4% | $2.41B+21.7% | ||
| $222.3M+9.1% | $217.9M+11.5% | $225.7M+35.0% | $213.5M+23.1% | $203.8M+2.5% | ||
| $788.9M+59.4% | $619.1M+8.5% | $550.2M-4.9% | $495M-7.7% | $494.8M+6.5% | ||
| $818.7M+56.4% | $649.2M+8.6% | $579.9M-4.1% | $523.5M-6.7% | $523.3M+7.5% | ||
| $818.7M+56.4% | $649.2M+8.6% | $579.9M-4.1% | $523.5M-6.7% | $523.3M+7.5% | ||
| 26.4%+4.7pp | 22.7%-2.7pp | 21.6%-5.3pp | 20.9%-5.6pp | 21.7%-2.9pp | ||
| $788.9M+59.4% | $619.1M+8.5% | $550.2M-4.9% | $495M-7.7% | $494.8M+6.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Neurocrine Biosciences's revenue?
- Neurocrine Biosciences (NBIX) generated $3.1B in revenue over the trailing twelve months, up 28.6% year over year.
- Is Neurocrine Biosciences profitable?
- Neurocrine Biosciences reported $668.6M in net income over the trailing twelve months, a 21.6% net margin.
- What are Neurocrine Biosciences's profit margins?
- Gross margin is 98.2% and operating margin is 25.4%, with a 21.6% net margin.
- What is Neurocrine Biosciences's earnings per share?
- Neurocrine Biosciences's diluted EPS over the trailing twelve months is $6.49.
- Where does Neurocrine Biosciences's income statement data come from?
- Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
